Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP047: Early fibrostenosis in Crohn's disease is associated with multiple susceptibility loci on Immunochip analysisECCO '17 Barcelona
Year: 2017
Authors:

Holvoet T.*1, Bossuyt P.2,3, Cleynen I.3, De Kock I.4, Hindryckx P.1, Vermeire S.3,5, Laukens D.1, De Vos M.1

1Ghent University Hospital, Dept. of Gastroenterology, Ghent, Belgium 2Imelda GI Clinical Research Center, Dept. of Gastroenterology, Bonheiden, Belgium 3University Hospitals Leuven, Dept. of Gastroenterology, Leuven, Belgium 4Ghent University Hospital, Radiology, Ghent, Belgium 5Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Dept. of Clinical and Experimental Medicine, Leuven, Belgium

DOP048: PROFILE trial: predicting outcomes for Crohn's disease using a molecular biomarkerECCO '17 Barcelona
Year: 2017
Authors:

Lee J.1,2, Biasci D.1, Noor N.*1,2, McKinney E.1, Ahmad T.3,4, Lewis N.5, Hart A.6,7, Lyons P.1, Parkes M.1,2, Smith K.1

1University of Cambridge, School of Clinical Medicine, Cambridge, United Kingdom 2Addenbrooke's Hospital NHS Trust, Department of Gastroenterology, Cambridge, United Kingdom 3University of Exeter, Exeter IBD and Pharmacogenetics Research Group, Exeter, United Kingdom 4Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom 5Nottingham University Hospitals NHS Trust, Department of Gastroenterology, Nottingham, United Kingdom 6St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom 7Imperial College, Faculty of Medicine, Department of Surgery & Cancer, London, United Kingdom

DOP049: Inflammatory dyskinesis: defects of NF-κB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Sellge G.*1, Papoutsopoulou S.2, Verdier J.1, Trautwein C.1, Bergey F.3, Burkitt M.4, Burkitt M.4, Sheibani R.5, Pierik M.6, Jonkers D.6, White M.2, Paszek P.2, Martins dos Santos V.3, Rosenstiel P.5, Müller W.2, Probert C.4 SysmedIBD Consortium2

1University Hospital RWTH Aachen, Department of Internal Medicine III, Aachen, Germany 2University of Manchester, Faculty of Life Sciences, Manchester, United Kingdom 3LifeGlimmer GmbH, Berlin, Germany 4University of Liverpool, Cellular and Molecular Physiology, Liverpool, United Kingdom 5Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany 6Maastricht University Medical Centre, Division Gastroenterology-Hepatology, Maastricht, Netherlands

DOP050: Serum proteomic analysis defines novel circulating inflammatory markers for Crohn's disease and response to anti-TNF therapyECCO '17 Barcelona
Year: 2017
Authors:

Korf H.*1,2, Sabino J.1, Ballet V.3, de Bruyn M.1,4, Van Assche G.3, Ferrante M.3, Vermeire S.3

1KULeuven, Translational Research in Gastrointestinal Disorders (TARGID), Clinical and Experimental Medicine, Leuven, Belgium 2KULeuven, Laboratory of Hepatology, Clinical and Experimental Medicine, Leuven, Belgium 3UZLeuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 4KULeuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Leuven, Belgium

DOP051: Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

van Haaften W.T.*1,2, Mortensen J.H.3, Olesen M.L.3,4, Karsdal M.A.3, Olinga P.2, Bay-Jensen A.-C.3, Dijkstra G.1

1University Medical Center Groningen, University of Groningen, Department of Gastro-enterology and Hepatology, Groningen, Netherlands 2University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands 3Nordic Bioscience, Biomarkers and Research, Herlev, Denmark 4Odense University Hospital, Department of Medical Gastroenterology, Odense, Denmark

DOP052: Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein and biopsy gene expression analysis: results from Ustekinumab phase 3 studiesECCO '17 Barcelona
Year: 2017
Authors:

Li K., Hayden K., Wadman E., Bhagat S., Emrich S., Jacobstein D., Gasink C., Brodmerkel C.

Janssen Research & Development, LLC, Spring House, Pennsylvania, United States

DOP053: The fecal microbiome as a tool for monitoring and predicting response outcomes in ustekinumab-treated, anti-TNFα refractory Crohn's disease patients: results from the CERTIFI studyECCO '17 Barcelona
Year: 2017
Authors:

Doherty M.K.*1, Koumpouras C.1, Telesco S.E.2, Monast C.2, Brodmerkel C.2, Schloss P.D.1

1University of Michigan Medical School, Department of Microbiology and Immunology, Ann Arbor, United States 2Janssen Research & Development, LLC, Spring House, United States

DOP054: High-throughput sequencing of T cell receptors from pediatric ulcerative colitis patients reveals distinct tissue-specific repertoiresECCO '17 Barcelona
Year: 2017
Authors:

Werner L.1, Nunberg M.1, Haberman Y.1, Lahad A.1, Turner D.2, Weiss B.1, Shouval D.*1

1Safra Children's Hospital, Department of Pediatric Gastroenterology, Tel Hashomer, Israel 2Shaare Zedak Medical Center, Jerusalem, Israel

DOP055: Results of the Fifth Scientific Workshop of the ECCO (II): clinical aspects of perianal fistulising Crohn's disease – the unmet needsECCO '17 Barcelona
Year: 2017
Authors:

Gecse K.*1, Sebastian S.2, De Hertogh G.3, Yassin N.4, Kotze P.5, Reinisch W.6, Spinelli A.7, Koutroubakis I.8, Katsanos K.9, Hart A.10, van den Brink G.11, Rogler G.12, Bemelman W.13

1Semmelweis University, First Department of Medicine, Budapest, Hungary 2Hull & East Yorkshire NHS Trust, Inflammatory Bowel Disease Unit, Hull, United Kingdom 3University of Leuven, Department of Pathology, Leuven, Belgium 4St Mark's Hospital and Academic Institute, Department of Colorectal Surgery, London, United Kingdom 5Catholic University of Paraná, Colorectal Surgery Unit, Curitiba, Brazil 6Medical University of Vienna, Department of Gastroenterology, Vienna, Austria 7Humanities University, Colorectal Surgery Unit, Humanitas Research Hospital, Milano, Italy 8University Hospital Heraklion, Department of Gastroenterology, Heraklion, Greece 9School of Health Sciences, Division of Gastroenterology, Department of Medicine, Ioannia, Greece 10St. Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom 11Academic Medical Centre, University of Amsterdam, Department of Gastroenterology, Amsterdam, Netherlands 12University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland 13Academic Medical Centre, University of Amsterdam, Department of Surgery, Amsterdam, Netherlands

DOP056: Pathophysiology of perianal fistulising diseaseECCO '17 Barcelona
Year: 2017
Authors:

Siegmund B.1, Feakins R.M.2, Barmias G.3, Coelho Ludvig J.4, Vieira Teixeira F.5, Rogler G.6, Scharl M.*7

1Charite Berlin, Berlin, Germany 2Royal London Hospital, London, United Kingdom 3Ethnikon and Kapodistriakon University of Athens, Athens, Greece 4Santa Isabel Hospital Blumenau, Santa Catarina, Brazil 5Gastrosaude Clinic, Sao Paulo, Brazil 6University Hospital Zürich, Zürich, Switzerland 7University Hospital Zürich, Division of Gastroenterology and Hepatology, Zürich, Switzerland

DOP057: Perianal pediatric Crohn's disease is associated with a distinct phenotype and greater inflammatory burdenECCO '17 Barcelona
Year: 2017
Authors:

Assa A.*1, Amitai M.2, Greer M.-L.3, Castro D.3, Cytter Kuint R.4, Martínez-Leόn M.5, Herman-Sucharska I.6, Coppenrath E.7, Anupindi S.8, Towbin A.9, Moote D.10, Konen O.11, Pratt L.-T.12, Grifitths A.3, Turner D.4

1Schneider Children's Medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel 2Sheba Medical Center, Department of Radiology, Ramat Gan, Israel 3Hospital for Sick Children, Toronto, Canada 4Shaare Zedek Medical Center, Jerusalem, Israel 5Hospital Regional Universitario Carlos Haya, Malaga, Spain 6Jagiellonian University in Cracow, Cracow, Poland 7University of Munich, Munich, Germany 8The Children's Hospital of Philadelphia, Philadelphia, United States 9Cincinnati Children's Hospital, Cincinnati, United States 10Connecticut Children's Medical Center, Hartford, United States 11Schneider Children's medical Center, Petach Tikva, Israel 12Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel

DOP058: Does biologic therapy increase the risk for fistula-associated mucinous adenocarcinoma in long standing perianal Crohn's disease?ECCO '17 Barcelona
Year: 2017
Authors:

Laureti S., Coscia M., Gentilini L., Gionchetti P., Renzi N., Rizzello F., Tanzanu M., Poggioli G.

University of Bologna, Department of Gastroenterology and Surgical Sciences, Bologna, Italy

DOP059: New human gut xenograft mouse model for intestinal fistulasECCO '17 Barcelona
Year: 2017
Authors:

Bruckner R.S.*1,2, Marsiano N.3, Nissim-Eliraz E.3, Nir E.3, Lang S.1,2, Spalinger M.1,2, Rogler G.1,4, Yagel S.5, Scharl M.1,4, Shpigel N.Y.3 SysmedIBD EU Research Consortium

1University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland 2University of Zurich, Zurich, Switzerland 3Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel 4University of Zurich, Zurich Center for Integrative Human Physiology, Zurich, Switzerland 5Hadassah University Hospital, Obstetrics and Gynecology, Jerusalem, Israel

DOP060: Real-world treatment pathway visualizations show low use of biologic therapies in Crohn's disease and ulcerative colitis in the United StatesECCO '17 Barcelona
Year: 2017
Authors:

Siegel C.*1, Yang F.2, Eslava S.2, Cai J.2

1Dartmouth-Hitchcock Medical Center, Lebanon, United States 2Celgene Corporation, Summit, United States

DOP061: Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety resultsECCO '17 Barcelona
Year: 2017
Authors:

Kim Y.H.*1, Ye B.D.2, Pesegova M.3, Alexeeva O.4, Osipenko M.5, Lahat A.6, Dorofeyev A.7, Salamon A.8, Fishman S.9, Levchenko O.10, Cheon J.H.11, Scribano M.L.12, Mateescu R.-B.13, Lee K.M.14, Eun C.S.15, Lee S.J.16, Lee S.Y.16

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea 2University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 3Krasnoyarsk Regional clinical hospital, Krasnoyarsk, Russian Federation 4Nizhny Novgorod Regional Clinical Hospital n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation 5Novosibirsk State Medical University, Novosibirsk, Russian Federation 6Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel and Sackler Faculty of Medicine, Tel Aviv University, Ramat-Gan, Israel 7Medical Center LLC Ukrainian German Antiulcer Gastroenterology Center BIK Kyiv, Kyiv, Ukraine 8Tolna Megyei Balassa János Kόrház, Szekszárd, Hungary 9Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine 11Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea 12Azienda Ospedaliera San Camillo Forlanini, Roma, Italy 13Gastroenterology Dept. at Colentina Clinical Hospital AND “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania 14St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, South Korea 15Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea 16CELLTRION, Inc., Incheon, South Korea

DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trialECCO '17 Barcelona
Year: 2017
Authors:

Jørgensen K.K.*1, Olsen I.C.2, Goll G.L.2, Lorentzen M.3, Bolstad N.4, Berset I.P.5, Haavardsholm E.A.2,6, Lundin K.E.6,7,8, Mørk C.9, Kvien T.K.2,6, Jahnsen J.1,6 and the Nor-Switch Study Group

1Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway 3Oslo University Hospital, Rikshospitalet, Department of Dermatology, Oslo, Norway 4Oslo University Hospital, Radiumhospitalet, Department of Medical Biochemistry, Oslo, Norway 5Ålesund Hospital, Department of Gastroenterology, Ålesund, Norway 6University of Oslo, Faculty of Medicine, Oslo, Norway 7Oslo University Hospital, Rikshospitalet, Department of Gastroenterology, Oslo, Norway 8Centre for Immune Regulation, Department of Immunology, Oslo, Norway 9Norwegian University of Science and Technology, Faculty of Medicine, Trondheim, Norway

DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Taxonera C.*1, Ponferrada A.2, Bermejo F.3, Gisbert J.P.4, Riestra S.5, Saro C.6, Cabriada J.L.7, Barreiro-de Acosta M.8, Barrio J.9, Flores E.10, Ferrer I.11, Hernandez A.12, Van Domselaar M.13, Olivares D.1, Alba C.1, Fernández-Salazar L.14, Merino O.15, Botella B.16, Ceballos D.17, Moral I.18, Peñate M.19, Algaba A.3 on behalf of the SEGURTB Study Group from GETECCU

1Hospital Clinico San Carlos, IdISSC, Madrid, Spain 2Hospital Infanta Leonor, Madrid, Spain 3Hospital de Fuenlabrada, Madrid, Spain 4Hospital Universitario de La Princesa, CIBERehd, Madrid, Spain 5Hospital Central De Asturias, Oviedo, Spain 6Hospital De Cabueñes, Gijόn, Spain 7Hospital San Eloy, Baracaldo, Spain 8Hospital de Santiago De Compostela, Santiago de Compostela, Spain 9Hospital Río Hortega, Valladolid, Spain 10Hospital Universitario Reina Sofía, CIBERehd, Cόrdoba, Spain 11Hospital de Manises, Manises, Spain 12Hospital Universitario De Canarias, Santa Cruz De Tenerife, Spain 13Hospital de Torrejόn, Madrid, Spain 14Hospital Clinico de Valladolid, Valladolid, Spain 15Hospital De Cruces, Bilbao, Spain 16Hospital Universitario Infanta Cristina, Madrid, Spain 17Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain 18Hospital Príncipe De Asturias, Madrid, Spain 19Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain

DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in inflammatory bowel disease patients with primary sclerosing cholangitisECCO '17 Barcelona
Year: 2017
Authors:

Ten Hove J.R.*1, Torres J.2, Castaneda D.2, Palmela C.2, Mooiweer E.1, Shah S.C.2, Colombel J.-F.2, Ullman T.2, Itzkowitz S.H.2, Oldenburg B.1

1University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands 2Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology, New York, United States

DOP065: Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in inflammatory bowel disease patients with primary sclerosing cholangitis; a six year experienceECCO '17 Barcelona
Year: 2017
Authors:

Hartery K., Williamson K., Chapman R., Atkinson N., East J.

John Radcliffe Hospital, Translation Gastroenterology Unit, Oxford, United Kingdom

DOP066: Strict surveillance colonoscopy should be performed for the ulcerative colitis patients who underwent ileorectal anastomosisECCO '17 Barcelona
Year: 2017
Authors:

Anzai H., Hata K., Ishihara S., Kishikawa J., Murono K., Kaneko M., Sasaki K., Yasuda K., Otani K., Nishikawa T., Tanaka T., Kiyomatsu T., Kawai K., Nozawa H., Watanabe T.

The University of Tokyo, Department of Surgery, Tokyo, Japan